Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Prinaberel. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 known ✓ | Q92731 | 20/20 | 1.00 |
| ▸ | ESR1 | P03372 | 17/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Prinaberel SCHEMBL3613805 | 0.99 | ESR2 (0.98) | ESR2ESR1 | |
| Prinaberel SCHEMBL14170053 | 0.93 | ESR2 (0.87) | ESR2ESR1 | |
| SCHEMBL27658556 | 0.89 | ESR2 (0.80) | ESR2ESR1 | |
| SCHEMBL12266841 | 0.88 | ESR2 (0.78) | ESR2ESR1 | |
| SCHEMBL14172911 | 0.88 | ESR2 (0.78) | ESR2ESR1 | |
| SCHEMBL1379189 | 0.86 | ESR2 (1.00) | ESR2ESR1 | |
| SCHEMBL22310237 | 0.85 | ESR2 (0.74) | ESR2ESR1 | |
| SCHEMBL14160974 | 0.85 | ESR2 (0.73) | ESR2ESR1 | |
| SCHEMBL14172914 | 0.85 | ESR2 (0.73) | ESR2ESR1 | |
| SCHEMBL14169838 | 0.85 | ESR2 (0.73) | ESR2ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 431 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240000768-A1 | METHOD FOR THE TREATMENT OF DISEASES ASSOCIATED WITH SULFATASE DEFICIENCIES | GEORG AUGUST UNIV GOTTINGEN STIFTUNG OFFENTLICHEN RECHTS UNIVS (DE) | 2024-01-04 | — | — | US | claimed |
| EP-4003332-A1 | PHARMACEUTICAL COMPOSITION OF MDM2 INHIBITOR AND USE THEREOF FOR PREVENTING AND/OR TREATING DISEASE | Ascentage Pharma (Suzhou) Co., Ltd. (CN) | 2022-06-01 | — | — | EP | claimed |
| US-20220142979-A1 | PHARMACEUTICAL COMPOSITION OF MDM2 INHIBITOR AND USE THEREOF FOR PREVENTING AND/OR TREATING DISEASE | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2022-05-12 | — | — | US | claimed |
| US-20110212923-A1 | Phosphate Derivatives of Substituted Benzoxazoles | PFIZER INC. | 2011-09-01 | — | — | US | claimed |
| JP-4689960-B2 | — | — | 2011-06-01 | — | — | JP | claimed |
| EP-2250180-A1 | PHOSPHATE DERIVATIVES OF SUBSTITUTED BENZOXAZOLES | Wyeth LLC (US) | 2010-11-17 | — | — | EP | claimed |
| US-20100113541-A1 | CRYSTAL FORMS OF 2-(3-FLUORO-4-HYDROXYPHENYL)-7-VINYL-1,3-BENZOXAZOL-5-OL | WYETH LLC (US) | 2010-05-06 | — | — | US | claimed |
| US-20090239920-A1 | PHARMACEUTICAL FORMULATIONS OF AN ANHYDRATE CRYSTAL FORM OF 2-(3-FLUORO-4-HYDROXYPHENYL)-7-VINYL-1,3-BENZOXAZOL-5-OL | WYETH (US) | 2009-09-24 | — | — | US | claimed |
| WO-2009100335-A1 | PHOSPHATE DERIVATIVES OF SUBSTITUTED BENZOXAZOLES | WYETH (US) | 2009-08-13 | — | — | WO | claimed |
| EP-2064195-A2 | CRYSTAL FORMS OF 2-(3-FLUORO-4-HYDROXYPHENYL)-7-VINYL-1,3-BENZOXAZOL-5-OL AND PHARMACEUTICAL FORMULATIONS THEREOF | Wyeth (US) | 2009-06-03 | — | — | EP | claimed |
| WO-2006060542-A2 | FORMULATIONS OF SUBSTITUTED BENZOXAZOLES | WYETH (US) | 2006-06-08 | — | — | WO | claimed |
| WO-2006060532-A2 | FORMULATIONS OF SUBSTITUTED BENZOXAZOLES | WYETH (US) | 2006-06-08 | — | — | WO | claimed |
| EP-1631283-A1 | ANTIARTHRITIC COMBINATIONS | Wyeth (US) | 2006-03-08 | — | — | EP | claimed |
| CN-1646504-A | Substituted benzoxazoles and analogs as estrogenic agents | WYETH CORP (US) | 2005-07-27 | — | — | CN | claimed |
| US-20040248865-A1 | Synergistic mixture containing antiinflammatory agents; rheumatic disorders | WYETH | 2004-12-09 | — | — | US | claimed |
| WO-2004103365-A1 | ANTIARTHRITIC COMBINATIONS | WYETH (US) | 2004-12-02 | — | — | WO | claimed |
| US-6794403-B2 | FOR TREATING OR INHIBITING INFLAMMATORY BOWEL DISEASE, CROHN'S DISEASE, ULCERATIVE PROCTITIS OR COLITIS PROSTATIC HYPERTROPHY, UTERINE LEIOMYOMAS, BREAST CANCER, ENDOMETRIAL CANCER, CARDIOVASCULAR DISEASE, ALZHEIMER'S DISEASE | WYETH | 2004-09-21 | — | — | US | claimed |
| EP-1451165-A1 | SUBSTITUTED BENZOXAZOLES AND ANALOGUES AS ESTROGENIC AGENTS | Wyeth (US) | 2004-09-01 | — | — | EP | claimed |
| US-20030199562-A1 | Substituted benzoxazoles as estrogenic agents | WYETH | 2003-10-23 | — | — | US | claimed |
| WO-2003050095-A1 | SUBSTITUTED BENZOXAZOLES AND ANALOGUES AS ESTROGENIC AGENTS | WYETH (US) | 2003-06-19 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220142979-A1 | PHARMACEUTICAL COMPOSITION OF MDM2 INHIBITOR AND USE THEREOF FOR PREVENTING AND/OR TREATING DISEASE | MDM2, TP53, BRCA1 | ESR2 2493/4885ESR1 1606/4885 |
| US-20030199562-A1 | Substituted benzoxazoles as estrogenic agents | ESR1, ESR2, ESRRA | ESR2 2/4885ESR1 1/4885 |
| US-20110212923-A1 | Phosphate Derivatives of Substituted Benzoxazoles | ESR2, GPER1, ESR1 | ESR2 1/4885ESR1 3/4885 |
| US-20040248865-A1 | Synergistic mixture containing antiinflammatory agents; rheumatic disorders | ESR2, ESRRA, ESRRB | ESR2 1/4885ESR1 16/4885 |
| US-20090239920-A1 | PHARMACEUTICAL FORMULATIONS OF AN ANHYDRATE CRYSTAL FORM OF 2-(3-FLUORO-4-HYDROXYPHENYL)-7-VINYL-1,3-BENZOXAZOL-5-OL | CYP2A7, CYP2F1, CYP3A5 | ESR2 152/4885ESR1 69/4885 |
| US-20100113541-A1 | CRYSTAL FORMS OF 2-(3-FLUORO-4-HYDROXYPHENYL)-7-VINYL-1,3-BENZOXAZOL-5-OL | GPER1, SHBG, NR5A2 | ESR2 7/4885ESR1 14/4885 |
| US-20240000768-A1 | METHOD FOR THE TREATMENT OF DISEASES ASSOCIATED WITH SULFATASE DEFICIENCIES | GAA, GBA1, STS | ESR2 3235/4885ESR1 4234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.